華森製藥(002907.SZ):參股創新藥研發合資公司完成工商註冊登記
格隆匯 7 月 6日丨華森製藥(002907.SZ)公佈,公司於2020年6月12日與四川大學華西醫院生物治療國家重點實驗室教授、“長江學者獎勵計劃”特聘教授楊勝勇簽訂了《關於共同對外投資設立創新藥研發公司之投資協議書》,雙方共同出資人民幣4520萬元,設立成都奧睿藥業有限公司(“奧睿藥業”),進行腫瘤、免疫1類創新藥物開發等業務。
2020年7月3日,奧睿藥業已完成工商註冊登記手續,並取得了成都高新技術產業開發區市場監督管理局核發的《營業執照》。
此次奧睿藥業的成立標誌着公司創新藥研發工作進入具體項目階段,奧睿藥業將以靶向細胞Necroptosis的小分子抑制劑的創新藥物研發項目為起點,通過3到5年時間圍繞國際前沿靶點逐步形成至少2個IND階段項目3個PCC階段項目的研發管線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.